BioAdaptives, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>BioAdaptives, Inc. filed its 2023 10-K, reporting significant assets and net income, with minimal debt.</b>

AI Summary

BIOADAPTIVES, INC. (BDPT) filed a Annual Report (10-K) with the SEC on April 10, 2024. BioAdaptives, Inc. reported total assets of $895,760,225 as of December 31, 2023. The company's net income for the fiscal year ending December 31, 2023, was $252,544,765. Total debt for BioAdaptives, Inc. was $10,000 as of December 31, 2023. Revenue for the fiscal year ending December 31, 2023, was $25,255,476. The company's cash and cash equivalents amounted to $1,600,000 as of December 31, 2023.

Why It Matters

For investors and stakeholders tracking BIOADAPTIVES, INC., this filing contains several important signals. The filing provides a comprehensive overview of BioAdaptives' financial health and operational status for the fiscal year 2023, crucial for investors assessing the company's performance and future prospects. Key financial figures such as total assets, net income, and debt levels offer insights into the company's stability and growth trajectory, informing investment decisions.

Risk Assessment

Risk Level: low — BIOADAPTIVES, INC. shows low risk based on this filing. The company has a low risk profile based on its substantial assets and positive net income reported in the 10-K filing, indicating financial stability.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand BioAdaptives' strategic initiatives and potential growth opportunities.

Financial Highlights

revenue

25,255,476

total Assets

895,760,225

total Debt

10,000

net Income

252,544,765

cash Position

1,600,000

Revenue Breakdown

Key Numbers

• 895,760,225 — Total Assets (As of December 31, 2023)
• 252,544,765 — Net Income (For the fiscal year ended December 31, 2023)
• 10,000 — Total Debt (As of December 31, 2023)
• 25,255,476 — Revenue (For the fiscal year ended December 31, 2023)
• 1,600,000 — Cash and Cash Equivalents (As of December 31, 2023)

Key Players & Entities

• BIOADAPTIVES, INC. (company) — Filer name
• BDPT (company) — Ticker symbol
• 2023-12-31 (date) — Fiscal year end
• 2024-04-10 (date) — Filing date
• Robert Ellis (person) — President and Member
• January One Thousand Twenty One (person) — Member
• 2620 REGATTA DRIVE (address) — Business address
• LAS VEGAS (location) — Business address city

FAQ

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-04-10: Filing Date — Date the 10-K was officially filed with the SEC.

Key Financial Figures

• $0.0001 — tion 12(g) of the Act: - Common Stock - $0.0001 par value ________________________ In
• $0.001 — ares of common stock for prices between $0.001-0.003. This filing is ongoing. The Com

Filing Documents

• bdpt_10k.htm (10-K) — 812KB
• bdpt_ex311.htm (EX-31.1) — 8KB
• bdpt_ex312.htm (EX-31.2) — 8KB
• bdpt_ex321.htm (EX-32.1) — 4KB
• bdpt_ex322.htm (EX-32.2) — 4KB
• bdpt_10kimg7.jpg (GRAPHIC) — 4KB
• 0001640334-24-000602.txt (&nbsp;) — 3955KB
• bdpt-20231231.xsd (EX-101.SCH) — 38KB
• bdpt-20231231_lab.xml (EX-101.LAB) — 234KB
• bdpt-20231231_cal.xml (EX-101.CAL) — 40KB
• bdpt-20231231_pre.xml (EX-101.PRE) — 197KB
• bdpt-20231231_def.xml (EX-101.DEF) — 106KB
• bdpt_10k_htm.xml (XML) — 538KB

Business

Business 4 Item 1A

Risk Factors

Risk Factors 8 Item 1B Unresolved Staff Comments 13 Item 2

Properties

Properties 13 Item 3

Legal Proceedings

Legal Proceedings 13 Item 4 Mine Safety Disclosures 13 Part II Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and 14 Item 6

Selected Financial Data

Selected Financial Data 16 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 19 Item 8

Financial Statements, Auditor's Notes and Supplemental Data

Financial Statements, Auditor's Notes and Supplemental Data 20 Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure Controls and Procedures Item 9B Other Information Part III Item 10 Directors, Executive Officers and Corporate Governance 38 Item 11

Executive Compensation

Executive Compensation 41 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 41 Item 13 Certain Relationships and Related Transactions, and Director Independence 42 Item 14 Principal Accountant Fees and Services 42 Part IV Item 15 Exhibits, Financial Statement Schedules 43 Item 16 Form 10-K Summary 43

Signatures

Signatures 2 Table of Contents Caution Regarding Forward-Looking Information Certain statements contained in this annual filing, including, without limitation, statements containing the words "believes", "anticipates", "expects" and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings. Given these uncertainties, readers of this Form 10-K and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments. Where You Can Find Information The public may read and copy any materials we file with the SEC in the SEC's Public Reference Section, Room 1580,100 F Street N.E., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Section by calling the SEC at 1-800-SEC-0330. Additionall

- Business

Item 1 - Business The Company's History BioAdaptives, Inc., ("BioAdaptives," the "Company," "we" or "us") was incorporated in the State of Delaware on April 19, 2013, as APEX 8 Inc. From inception through October 21, 2013, the Company was in the developmental stage and conducted virtually no business operations, other than organizational activities and preparation of a registration statement on Form 10-12g (the "Registration Statement"), which was filed with the U.S. Securities and Exchange Commission on May 3, 2013. On June 11, 2013, the SEC staff informed the Company that it had no further comments. On January 10, 2014, the SEC notified the Company that the registration statement was effective and on July 9, 2014, the Company's shares commenced trading in the Over-the-Counter market under the trading symbol BDPT. On March 31, 2017, the Company filed a Form 15-15D with the SEC, terminating its status as an SEC-reporting company; it was current in its Continuous Disclosure obligations at that time. The Company continued to provide financial and other reports to shareholders and the public by means of the Alternative Reporting System operated by OTC Markets Group, Inc. Its shares continued to trade in the OTC market and it also continued to execute its business plan. On May 10, 2019, the Company filed a Form 10-12g with the SEC, re-entering the Continuous Disclosure program and registering its common stock under Section 12(g) of the Securities Exchange Act of 1934. On August 1, 2019, the SEC staff informed the Company that it had no further comments on this filing. On September 11, 2019, the Company appointed Robert Ellis as President and Ron Lambrecht as Chief Financial Officer. Dr. Jacobs remained as Chief Executive Officer. On February 6, 2020, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series A Preferred Stock. The Series A has enhanced voting and conversion privileges and can be used by t

View Full Filing

View this 10-K filing on SEC EDGAR